Navigation Links
Axioskop 40

ProductsAxioskop 40
Company Carl Zeiss MicroImaging, Inc.
Item Axioskop 40
Features 
  • Ergonomic design: developed according to the latest scientific findings.
  • Ideal 15 angle: ergotube and photo-ergotube, vertically adjustable up to 50 mm
  • Leading optics: uncompromising quality from Carl Zeiss
  • Innovative contrast: Varel and oblique illumination
  • High-end fluorescence: outstanding contrast, highest transmission
  • Practical: closed ceramic-top stage surface, ergo-drives
  • Space-saving stand: extremely sturdy
  • High-quality processing: long-lasting robust mechanics
  • Efficient illumination: transmitted light lamps with lifetime of approximately 4000 hours
  • Reliable results: the new LED with semi-Khler mode - ensures reliable results thanks to its constant color temperature.
Description The Axioskop 40 FL laboratory microscope from Carl Zeiss combines optical quality and mechanical stability of research-class instruments with a user-friendly ergonomic design. The microscope is ideal for routine clinical applications in pathology, histology, cytology, and hematology. In addition, it has numerous applications in fluorescence microscopy, such as immunofluorescence or FISH. The unit also features a new 50mm height adjustable, 20 viewing angle ergonomic binocular/phototube tube and X-Y extendable/friction control ergonomic X-Y stage. The microscope comes standard with a permanently aligned 4000-hr tungsten-halogen light source.
Info Carl Zeiss MicroImaging, Inc.
Customer Service: (800) 233-2343
Web site: http://www.zeiss.com/micro

Related medicine products :

1. Thermoline™ Blood Component Thawing System MT-202
2. Thermoline™ Blood Component Thawing System MT-204
3. Roche OMNI C Blood Gas Analyzer
4. RapidLab 248 Blood Gas Analyzer
5. Rapidlab 348 Blood Gas Analyzer
6. ABL700 Blood gas analyzer
7. ABL77 Blood Gas Analyzer
8. ABL555 Blood gas analyzer
9. ABL5 Blood gas analyzer
10. Automated Blood Coagulation Analyzer
11. Blood Coagulation Analyzer CG Series
TAG: Axioskop
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18UNC awarded 246 2 million renewal grant by NIH Rare Diseases Research Network 10336 1UNC awarded 246 2 million renewal grant by NIH Rare Diseases Research Network 10336 2 Tired Doctors More Prone to Errors 59371 1 Tired Doctors More Prone to Errors 59371 2 Tired Doctors More Prone to Errors 59371 3Discover Red Mangos New Seasonal Flavor 3A Pumpkin Spice 59366 1Discover Red Mangos New Seasonal Flavor 3A Pumpkin Spice 59366 2